Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Accounts Payables (2016 - 2026)

Pharma-Bio Serv's Accounts Payables history spans 16 years, with the latest figure at $869964.0 for Q1 2026.

  • For Q1 2026, Accounts Payables fell 8.57% year-over-year to $869964.0; the TTM value through Jan 2026 reached $869964.0, down 8.57%, while the annual FY2025 figure was $991169.0, 12.1% down from the prior year.
  • Accounts Payables reached $869964.0 in Q1 2026 per PBSV's latest filing, down from $991169.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $1.7 million in Q3 2022 to a low of $869964.0 in Q1 2026.
  • Average Accounts Payables over 5 years is $1.3 million, with a median of $1.1 million recorded in 2024.
  • Peak YoY movement for Accounts Payables: grew 1.54% in 2023, then plummeted 33.78% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $1.6 million in 2022, then decreased by 9.95% to $1.5 million in 2023, then dropped by 23.15% to $1.1 million in 2024, then decreased by 12.1% to $991169.0 in 2025, then dropped by 12.23% to $869964.0 in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Accounts Payables are $869964.0 (Q1 2026), $991169.0 (Q4 2025), and $874379.0 (Q3 2025).